Display options
Share it on

J Immunol. 2009 Jul 15;183(2):945-52. doi: 10.4049/jimmunol.0900921. Epub 2009 Jun 24.

Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.

Journal of immunology (Baltimore, Md. : 1950)

Cristina Maria Costantino, Hidde L Ploegh, David A Hafler

Affiliations

  1. Division of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 19553543 PMCID: PMC2752291 DOI: 10.4049/jimmunol.0900921

Abstract

Although it has long been known that human CD4(+) T cells can express functional class II MHC molecules, the role of lysosomal proteases in the T cell class II MHC processing and presentation pathway is unknown. Using CD4(+) T cell clones that constitutively express class II MHC, we determined that cathepsin S is necessary for invariant chain proteolysis in T cells. CD4(+)HLA-DR(+) T cells down-regulated cathepsin S expression and activity 18 h after activation, thereby ceasing nascent class II MHC product formation. This blockade resulted in the loss of the invariant chain fragment CLIP from the cell surface, suggesting that-like professional APC-CD4(+) HLA-DR(+) cells modulate self-Ag presentation as a consequence of activation. Furthermore, cathepsin S expression and activity, and concordantly cell surface CLIP expression, was reduced in HLA-DR(+) CD4(+) T cells as compared with B cells both in vitro and ex vivo.

References

  1. J Exp Med. 1979 Aug 1;150(2):246-55 - PubMed
  2. Cell. 1996 Feb 23;84(4):543-50 - PubMed
  3. Immunology. 2005 Jun;115(2):170-8 - PubMed
  4. Curr Opin Immunol. 2004 Feb;16(1):96-102 - PubMed
  5. J Exp Med. 1980 Jan 1;151(1):91-100 - PubMed
  6. Immunity. 2005 Nov;23(5):491-502 - PubMed
  7. Science. 2005 Jul 8;309(5732):264-8 - PubMed
  8. Immunol Lett. 1994 Dec;43(3):189-93 - PubMed
  9. Nat Immunol. 2004 Sep;5(9):909-18 - PubMed
  10. J Immunol. 2002 Jan 15;168(2):763-70 - PubMed
  11. J Immunol. 1991 Aug 1;147(3):774-80 - PubMed
  12. Immunity. 1996 Apr;4(4):357-66 - PubMed
  13. Immunol Rev. 1999 Dec;172:109-20 - PubMed
  14. J Med Chem. 1995 Aug 18;38(17):3193-6 - PubMed
  15. Nature. 1988 Aug 11;334(6182):530-2 - PubMed
  16. Semin Immunol. 2007 Aug;19(4):236-44 - PubMed
  17. J Immunol. 1989 Jul 15;143(2):762-9 - PubMed
  18. J Exp Med. 1978 Nov 1;148(5):1440-5 - PubMed
  19. J Immunol. 2005 Jun 1;174(11):7066-74 - PubMed
  20. J Cell Biol. 1997 Apr 7;137(1):51-65 - PubMed
  21. Arch Virol. 1995;140(2):375-82 - PubMed
  22. J Exp Med. 1992 Jul 1;176(1):177-86 - PubMed
  23. Immunity. 1994 Dec;1(9):763-74 - PubMed
  24. J Clin Invest. 1998 Jun 1;101(11):2351-63 - PubMed
  25. Nature. 1998 Dec 17;396(6712):695-9 - PubMed
  26. Cell. 1995 Jul 14;82(1):155-65 - PubMed
  27. Eur J Immunol. 1986 Mar;16(3):248-51 - PubMed
  28. Science. 2000 Oct 6;290(5489):92-7 - PubMed
  29. Int Immunol. 1995 Sep;7(9):1515-8 - PubMed
  30. Hum Immunol. 2004 Apr;65(4):282-90 - PubMed
  31. PLoS One. 2008 Feb 13;3(2):e1576 - PubMed
  32. Science. 1996 Mar 1;271(5253):1278-81 - PubMed
  33. Annu Rev Immunol. 2005;23:975-1028 - PubMed
  34. J Immunol. 2006 Apr 15;176(8):4622-31 - PubMed
  35. Science. 1998 Apr 17;280(5362):450-3 - PubMed
  36. Immunol Rev. 1999 Dec;172:121-9 - PubMed
  37. EMBO J. 1992 Feb;11(2):411-6 - PubMed
  38. Curr Protoc Cell Biol. 2001 May;Chapter 2:Unit 2.4 - PubMed
  39. Nat Rev Immunol. 2003 Jun;3(6):472-82 - PubMed
  40. J Immunol. 1990 Dec 15;145(12):4018-25 - PubMed
  41. J Immunol. 2004 May 1;172(9):5495-503 - PubMed
  42. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2110-4 - PubMed
  43. EMBO J. 2000 Mar 15;19(6):1187-94 - PubMed
  44. J Exp Med. 2000 Apr 3;191(7):1177-86 - PubMed
  45. J Exp Med. 1988 Feb 1;167(2):345-52 - PubMed
  46. Eur J Immunol. 2001 Dec;31(12):3726-36 - PubMed
  47. J Immunol. 2008 Mar 1;180(5):2876-85 - PubMed

Substances

MeSH terms

Publication Types

Grant support